Loading paragraph...
Today's Biggest Stock Losers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| KD | Kyndryl | $10.58 | -$12.91 | -54.96% | 779.6K | $5.4B | $10.11$44.20 |
| PLYX | Polaryx Therapeutics | $6.25 | -$2.66 | -29.85% | 102.4K | $422M | $2.51$48.91 |
| PFSA | Profusa | $3.12 | -$1.25 | -28.64% | 229.6K | $378M | $3.10$957.00 |
| VHUB | VenHub Global | $3.47 | -$1.37 | -28.26% | 407.1K | $362M | $3.40$40.30 |
| FLYE | Fly-E Group | $2.59 | -$0.87 | -25.14% | 224.9K | $5.6M | $2.50$161.80 |
| MNDY | Monday.com | $76.29 | -$21.71 | -22.15% | 315.6K | $5.0B | $73.01$342.64 |
| HIMS | Hims & Hers Health | $18.38 | -$4.65 | -20.18% | 2.7M | $5.2B | $16.36$72.98 |
| RDIB | Reading International | $10.77 | -$2.69 | -19.98% | 25.1K | $306M | $5.81$17.40 |
| MPAA | Motorcar Parts Of America | $10.67 | -$2.47 | -18.80% | 8.4K | $257M | $6.04$18.12 |
| PGY | Pagaya Technologies | $15.16 | -$3.48 | -18.67% | 632.3K | $1.5B | $8.50$44.99 |
| NNNN | Anbio Biotechnology | $21.11 | -$4.54 | -17.70% | 232 | $1.1B | $5.00$55.65 |
| CLF | Cleveland-Cliffs | $12.33 | -$2.40 | -16.29% | 1.7M | $8.4B | $5.63$16.70 |
| IBG | Innovation Beverage Group | $4.00 | -$0.78 | -16.28% | 47K | $3.3M | $3.27$49.25 |
| SXTC | China Sxt Pharmaceuticals | $2.54 | -$0.46 | -15.33% | 4.3M | $2.6M | $2.34$1,176.00 |
| PLTZ | Tidal Trust II - Defiance Daily Target 2x Short Pltr ETF | $32.41 | -$5.37 | -14.21% | 1.5M | - | $19.91$75.28 |
| MAXN | Maxeon Solar Technologies | $3.37 | -$0.52 | -13.37% | 393.7K | $66M | $2.46$6.02 |
| SMX | Smx (Security Matters) Public | $13.80 | -$2.03 | -12.82% | 3.6M | $138M | $3.12$9,134.28 |
| ATLN | Atlantic International | $3.09 | -$0.36 | -10.44% | 30.7K | $216M | $1.16$6.50 |
Related Articles
Featured Article
Hims & Hers Takes On Novo Nordisk: What We Know Right Now
Travis Hoium|Feb 5, 2026
Hims & Hers fell on fear that Novo Nordisk would take action against the company's new oral GLP-1, but there's more to the story.
HUGE News: Hims & Hers Adds Cancer Testing to Labs Offering
Travis Hoium|Feb 4, 2026
Hims & Hers is moving beyond prescriptions to preventative testing.
Stocks to Love in 2026
Motley Fool Staff|Jan 11, 2026
Are you looking for investment opportunities in 2026?
Why Is Hims & Hers Stock Falling, and Should Investors Buy the Dip?
Parkev Tatevosian, CFA|Nov 26, 2025
The healthcare industry is ripe for disruption.
Monday.com Stock Is Crashing. Time to Buy the Dip?
Timothy Green|Nov 10, 2025
The software company's slight guidance cut tanked the stock.
Hims & Hers Revenue Continues to Surge. Is It Time to Buy the Stock?
Geoffrey Seiler|Nov 9, 2025
The company continues to have a strong growth outlook ahead.
Hims & Hers Stock Jumps 9% After Huge Announcement
Travis Hoium|Oct 16, 2025
New products are coming to the Hers platform.
1 Growth Stock Down 30% You Don't Want to Miss On
Neil Rozenbaum|Oct 6, 2025
The recent pullback is a blessing in disguise.
Cleveland-Cliffs Stock Just Keeps Dropping. Buying Opportunity, or a Sign to Steer Clear?
Reuben Gregg Brewer|Oct 1, 2025
Cleveland-Cliffs is losing money as the steel industry deals with a downturn, which is exactly why you might want to buy it.
A Healthcare Debate: Progyny vs. Hims & Hers
Motley Fool Staff|Sep 26, 2025
Motley Fool analysts take a look.
